PTC:2 期实验失败,并以1.5亿美元出售FDA优先审查凭证

生物药大时代
28 Nov 2024

声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。近日,PTC Therapeutics宣布,一项针对实验性渐冻症药物utreloxastat的2期临床试验在主要终点和所有次要终点均失败。研究人员根据ALSFRS-R的综合症状评分,正在研究这种药物是否可以减缓疾病的进展,最终确定不能,公司表示并不打算...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10